Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Research & Development: 2020-2024

Historic Research & Development for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $66.0 million.

  • Taysha Gene Therapies' Research & Development rose 72.25% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.8 million, marking a year-over-year increase of 21.18%. This contributed to the annual value of $66.0 million for FY2024, which is 16.24% up from last year.
  • Taysha Gene Therapies' Research & Development amounted to $66.0 million in FY2024, which was up 16.24% from $56.8 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year Research & Development high stood at $131.9 million for FY2021, and its period low was $31.9 million during FY2020.
  • For the 3-year period, Taysha Gene Therapies' Research & Development averaged around $71.3 million, with its median value being $66.0 million (2024).
  • As far as peak fluctuations go, Taysha Gene Therapies' Research & Development spiked by 313.71% in 2021, and later crashed by 37.72% in 2023.
  • Taysha Gene Therapies' Research & Development (Yearly) stood at $31.9 million in 2020, then soared by 313.71% to $131.9 million in 2021, then slumped by 30.90% to $91.2 million in 2022, then slumped by 37.72% to $56.8 million in 2023, then climbed by 16.24% to $66.0 million in 2024.